GSGTF (Gensight Biologics) Short-Term Debt: $3.86 Mil (As of Dec. 2025)


What is Gensight Biologics Short-Term Debt?

Gensight Biologics GSGTF Short-Term Debt is $3.86 Mil as of Dec. 2025. The stock has 8 warning signs investors should review.

Gensight Biologics's Short-Term Debt for the quarter that ended in Dec. 2025 was $3.86 Mil.

Gensight Biologics's quarterly Short-Term Debt increased from Dec. 2024 ($13.94 Mil) to Jun. 2025 ($15.65 Mil) but then declined from Jun. 2025 ($15.65 Mil) to Dec. 2025 ($3.86 Mil).

Gensight Biologics's annual Short-Term Debt declined from Dec. 2023 ($18.11 Mil) to Dec. 2024 ($13.94 Mil) and declined from Dec. 2024 ($13.94 Mil) to Dec. 2025 ($3.86 Mil).

Gensight Biologics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Gensight Biologics Short-Term Debt Related Terms

Gensight Biologics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Gensight Biologics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gensight Biologics Short-Term Debt Chart

Gensight Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.28 1.63 18.11 13.94 3.86

Gensight Biologics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.11 6.23 13.94 15.65 3.86
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $3.86 Mil mean?
Gensight Biologics (GSGTF) has a Short-Term Debt of $3.86 Mil as of Dec. 2025.
Is Gensight Biologics' Short-Term Debt too high?
Gensight Biologics' current Short-Term Debt is $3.86 Mil.
How does Gensight Biologics' Short-Term Debt compare to VRTX and REGN?
Gensight Biologics' Short-Term Debt of $3.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Gensight Biologics's current Short-Term Debt is $3.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (GSGTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.09 — trading 125% above its estimated fair value. The current Short-Term Debt is $3.86 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current Short-Term Debt is $3.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gensight Biologics Business Description

Address 74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.